| Name | Title | Contact Details |
|---|---|---|
Brian Walter |
Vice President of Regulatory Affairs | Profile |
About Arrhythmia Research Technology, Inc. The Company through itswholly-owned subsidiary, Micron Products, Inc. manufacturescomponents, devices and equipment primarily for the medical anddefense industries. Micron is engaged in the production and sale ofsilver/silver chloride coated and conductive resin sensors used ascomponent parts in the manufacture of integrated disposableelectrophysiological sensors. These disposable medical devices areused worldwide in the monitoring of electrical signals in variousmedical applications. The Company has expanded into customthermoplastic injection molded products with a full array of design,engineering and production services and management. The addition ofan orthopedic implant machining operation produces quick-turn, highvolume and patient-specific, finished orthopedic implants. TheCompany also has developed and distributes a customizable proprietarysignal-averaging electrocardiography (SAECG) software used in thedetection of certain heart arrhythmias and that is reconfigurable fora variety of hardware platforms.
Alliance HNI is a Portage, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
CardioMed Supplies is a Lindsay, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Perosphere Technologies is a private medical technologies company focused on developing coagulation diagnostics and medical device based drug delivery systems.
The RNS® System is an award-winning technology developed and manufactured in Silicon Valley that has been recognized for its innovation. Similar to a pacemaker that monitors and responds to heart rhythms, the RNS System is the world`s first and only medical device that can monitor and respond to brain activity. NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. The company`s initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.In addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.